Multifocal visual evoked potential latency analysis: Predicting progression to multiple sclerosis

Archives of Neurology

Volumn 63, Issue 6, 2006, Pages 847-850

  Fraser, Clare ^a   Klistorner, Alexander ^a   Graham, Stuart ^a   Garrick, Raymond ^b   Billson, Francis ^a   Grigg, John ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPREDNISOLONE; STEROID;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EVOKED VISUAL RESPONSE; HUMAN; MULTIPLE SCLEROSIS; OPTIC NEURITIS; PRIORITY JOURNAL;

ANALYSIS OF VARIANCE; EVOKED POTENTIALS, VISUAL; FEMALE; HUMANS; MALE; MULTIPLE SCLEROSIS; OPTIC NEURITIS; PATTERN RECOGNITION, VISUAL; PHOTIC STIMULATION; PROSPECTIVE STUDIES; REACTION TIME;

EID: 33745078416     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.63.6.847     Document Type: Article

References (22)

1. Frohman EM, Frohman TC, Zee DS, McColl R, Galetta S. The neuro-ophthalmology of multiple sclerosis. Lancet Neurol. 2005;4:111-121.
2. Halliday AM, MacDonald W, Mushin J. Delayed visual evoked response in optic neuritis. Lancet. 1972;1:982-985.
3. Halliday AM, McDonald W, Mushin J. Visual evoked response in the diagnosis of multiple sclerosis. Br Med J. 1973;4:661-664.
4. Optic Neuritis Study Group. The 5-year risk of MS after optic neuritis: experience of the Optic Neuritis Treatment Trial. Neurology. 1997;49:1404-1413.
5. Soderstrom M. Optic neuritis and multiple sclerosis. Acta Ophthalmol Scand. 2001;79:223-227.
6. Lee A, Brazis P. Clinical Pathways in Neuro-Ophthalmology: An Evidence-Based Approach, 2nd edition. New York, NY: Thieme; 2003.
7. CHAMPS Study Group. MRI predictors of early conversion to clinically definite multiple sclerosis in the CHAMPS placebo group. Neurology. 2002;59:998-1005.
8. Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain. 1997;120:2059-2069.
9. Polman CH, Reingold S, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald criteria." Ann Neurol. 2005;58:840-846.
10. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50:121-127.
11. Keltner JL, Johnson CA, Spurr JO, Beck RW. Baseline visual field profile of optic neuritis: the experience of the optic neuritis treatment trial. Arch Ophthalmol. 1993;111:231-234.
12. Graham SL, Klistorner AI, Grigg JR, Billson FA. Objective VEP perimetry in glaucoma: asymmetry analysis to identify early deficits. J Glaucoma. 2000;9:10-19.
13. Klistorner AI, Graham SL. Multifocal pattern VEP perimetry: analysis of sectoral waveforms. Doc Ophthalmol. 1999;98:183-196.
14. Klistorner AI, Graham SL, Grigg JR, Billson FA. Multifocal topographic visual evoked potential: improving objective detection of local visual field defects. Invest Ophthalmol Vis Sci. 1998;39:937-950.
15. Klistorner AI, Graham SL. Electroencephalogram-based scaling of multifocal visual evoked potentials: effect on intersubject amplitude variability. Invest Ophthalmol Vis Sci. 2001;42:2145-2152.
16. Goldberg I, Graham SL, Klistorner AI. Multifocal objective perimetry in the detection of glaucomatous field loss. Am J Ophthalmol. 2002;133:29-39.
17. Beck RW, Trobe JD, Moke PS, et al. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol. 2003;121:944-949.
18. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med. 2000;343:898-904.
19. O'Connor P. The effects of intramuscular interferon beta-1a in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS. Clin Ther. 2003;25:2865-2874.
20. Dalton CM, Brex PA, Miszkiel KA, Hickman SJ, et al. Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann Neurol. 2002;52:47-53.
21. Tintore M, Rovira A, Rio J, Montalban X. New diagnostic criteria for multiple sclerosis: application in the first demyelinating episode. Neurology. 2003;60:27-30.
22. Frohman EM, Goodin DS, Calabresi PA, et al. The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2003;61:602-611.